Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus;Evolución del título de anticuerpos contra el receptor tipo M de la fosfolipasa A2 y respuesta clínica en pacientes con nefropatía membranosa idiopática tratados con tacrolimus

Nefrologia

Volumn 34, Issue 4, 2014, Pages 491-497

  Segarra Medrano, Alfons ^a   Jatem Escalante, Elías ^b   Carnicer Cáceres, Clara ^a   Agraz Pamplona, Irene ^a   Teresa Salcedo, M ^a   Valtierra, Naiara ^a   Ostos Roldán, Elena ^a   Arredondo, Karla V ^a   Jaramillo, Juliana ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Anti PLRA2 antibodies; Idiopathic membranous nephropathy; Tacrolimus

Indexed keywords

ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPASE A2 RECEPTOR; PLA2R1 PROTEIN, HUMAN; TACROLIMUS;

ADULT; BLOOD; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PREDICTIVE VALUE; TREATMENT OUTCOME;

ADULT; ANTIBODIES; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, PHOSPHOLIPASE A2; TACROLIMUS; TREATMENT OUTCOME;

EID: 84905083156     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2014.Jun.12536     Document Type: Article

References (23)

1. Donadio JV, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, et al. Idiopathic membranous nephropathy. Kidney Int 1988;33:708-15.
2. Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulopathy. Lancet 2004;364:1194-6.
3. Fulladosa X, Praga M, Segarra A, Martínez Ara J. Glomerulonefritis membranosa. Nefrologia 2007;27(Suppl 2):70-86.
4. KDIGO Clinical Practice Guideline for glomerulonephritis idiopathic membranous nephropathy. Kidney Int Suppl 2012;2:186-97.
5. Donadio JV, Holley KE, Andersons CF, Taylor WF. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 1974;6:431-9.
6. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-4.
7. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998;9:444-50.
8. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18:1899-904.
9. Hofstra JM, Branten AJ, Wirtz JJ, Noordzij TC, du Buf-Vereijken PW, Wetzels JF. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2010;25:129-36.
10. van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 2014;25:150-8.
11. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 1995;47:1130-5.
12. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. Cyclosporine in patients with steroid resistant membranous nephropathy: A randomized trial. Kidney Int 2001;59:1484-90.
13. Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007;71:924-30.
14. 2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21.
15. 2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011;22:1137-43.
16. 2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011;26:2526-32.
17. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011;6:1286-91.
18. 2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013;83:940-8.
19. 2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543-50.
20. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009;4:734-44.
21. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 2007;72:1429-47.
22. 2R antibodies in membranous nephropathy: ready for routine clinical practice? Neth J Med 2012;70:109-13.
23. Hofstra JM, Fervenza FC, Wetzels JF. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 2013;9:443-58.